0001752724-21-269098.txt : 20211214 0001752724-21-269098.hdr.sgml : 20211214 20211214121643 ACCESSION NUMBER: 0001752724-21-269098 CONFORMED SUBMISSION TYPE: N-CEN PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20210930 FILED AS OF DATE: 20211214 DATE AS OF CHANGE: 20211214 EFFECTIVENESS DATE: 20211214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VANGUARD QUANTITATIVE FUNDS CENTRAL INDEX KEY: 0000799127 IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: N-CEN SEC ACT: 1940 Act SEC FILE NUMBER: 811-04526 FILM NUMBER: 211490201 BUSINESS ADDRESS: STREET 1: 100 VANGUARD BLVD STREET 2: P O BOX 2600 CITY: MALVERN STATE: PA ZIP: 19355 BUSINESS PHONE: 6106691000 MAIL ADDRESS: STREET 1: 100 VANGUARD BLVD STREET 2: PO BOX 2600 CITY: VALLEY FORGE STATE: PA ZIP: 19482 FORMER COMPANY: FORMER CONFORMED NAME: VANGUARD QUANTITATIVE FUNDS / DATE OF NAME CHANGE: 20010503 0000799127 S000002913 Vanguard Growth and Income Fund C000007979 Investor Shares VQNPX C000007980 Admiral Shares VGIAX N-CEN 1 primary_doc.xml X0404 N-CEN LIVE 0000799127 XXXXXXXX 811-04526 true false false N-1A true VANGUARD QUANTITATIVE FUNDS 811-04526 0000799127 5493007AJT3TIGZKYP66 100 VANGUARD BOULEVARD MALVERN 19355 US-PA US 6106691000 State Street Bank and Trust One Lincoln Street Boston 20111 617-662-3839 The accounts, books, and other documents required to be maintained by Registrant pursuant to section 31(a) of the Investment Company Act of 1940 and the Rules thereunder. N N N-1A 1 Y Andre F. Perold N/A N Mortimer J. Buckley 002167630 Y David Thomas N/A N Mark Loughridge N/A N Emerson U. Fullwood N/A N Sarah Bloom Raskin N/A N Peter F. Volanakis N/A N Scott C. Malpass N/A N F. Joseph Loughrey N/A N Amy Gutmann N/A N Deanna Mulligan N/A N John E. Schadl 006931790 100 Vanguard Boulevard Malvern 19355 XXXXXX N N N N N N VANGUARD MARKETING CORP. 8-21570 000007452 N/A Y N PRICEWATERHOUSECOOPERS LLP 000000238 5493002GVO7EO8RNNS37 N N N N N N N VANGUARD GROWTH AND INCOME FUND S000002913 BZQEUHY2KE1ZMR7IWO60 N 2 0 0 N/A N N Y N N The Vanguard Group, Inc. 5493002789CX3L0CJP65 Y N Cash collateral reinvestment fee Administrative fee 6580985.88999999 246017.86000000 Rule 32a-4 (17 CFR 270.32a-4) Rule 17a-7 (17 CFR 270.17a-7) N N N N Los Angeles Capital Management and Equity Research, Inc. 801-60934 000119033 549300DZCL1LRBNVU327 N The Vanguard Group, Inc. 801-11953 000105958 5493002789CX3L0CJP65 N D. E. Shaw Investment Management, LLC 801-64222 000135284 549300ZUDX4FNDGUSO63 N The Vanguard Group, Inc. 084-00772 5493002789CX3L0CJP65 Y N N Refinitiv US LLC 20-4530702 TIN N Markit North America INC 13-4153988 TIN N ICE Data Pricing and Refernce Data LLC 13-36687789 TIN N Markit Group Limited 549300HLPTRASHS0E726 GB N Bloomberg Finance LP 5493001KJTIIGC8Y1R12 N ITG Analytics Inc 41-2190282 TIN N JPMorgan Chase Bank 7H6GLXDRUGQFU57RNE97 N N State Street Bank and Trust Company 571474TGEMMWANRLN572 N N Bank - section 17(f)(1) (15 U.S.C. 80a-17(f)(1)) N The Vanguard Group, Inc. 5493002789CX3L0CJP65 Y N N State Street Bank and Trust Company 571474TGEMMWANRLN572 N Y THE VANGUARD GROUP, INC. 5493002789CX3L0CJP65 Y N Y Instinet, LLC 008-23669 000007897 549300MGMN3RKMU8FT57 42196.87999999 BofA Securities, Inc. 008-69787 000283942 549300HN4UKV1E2R3U73 36187.33999999 Sanford C. Bernstein & Co., LLC 008-52942 000104474 549300I7JYZHT7D5CO04 40680.72000000 Goldman Sachs & Co. LLC 008-00129 000000361 FOR8UP27PHTHYVLBNG30 103151.26999999 UBS Securities LLC 008-22651 000007654 T6FIZBDPKLYJKFCRVK44 57570.00000000 Jefferies LLC 008-15074 000002347 58PU97L1C0WSRCWADL48 202570.39000000 Barclays Capital Inc. 008-41342 000019714 AC28XWWI3WIBK2824319 39520.74999999 Morgan Stanley & Co. LLC 008-15869 000008209 9R7GPTSO7KV3UQJZQ078 146955.17999999 J.P. Morgan Securities LLC 008-35008 000000079 ZBUT11V806EZRVTWT807 56256.93000000 Credit Suisse Securities (USA) LLC 008-00422 000000816 1V8Y6QCX6YMJ2OELII46 91509.57999999 872139.24999993 Vanguard Market Liquidity Fund N/A N/A 1I6HV0TLSTR3A4XQ6L78 5530568849.00000000 Vanguard U.S. Growth Fund N/A N/A 4IESARCYK2P68FL7C831 9473697.09999999 BofA Securities, Inc. 008-69787 000283942 549300HN4UKV1E2R3U73 80502976.09000000 Morgan Stanley & Co. LLC 008-15869 000008209 9R7GPTSO7KV3UQJZQ078 1121427814.80999990 J.P. Morgan Securities LLC 008-35008 000000079 ZBUT11V806EZRVTWT807 915408.78000000 Deutsche Bank Securities Inc. 008-17822 000002525 9J6MBOOO7BECTDTUZW19 899783.44000000 6743788529.21999989 Y 12720836000.37583400 Committed 4300000000.00000000 N N N N true INTERNAL CONTROL RPT 2 quantitativefunds11.19.txt Report of Independent Registered Public Accounting Firm To the Board of Fundees of Vanguard Quantitative Funds and Shareholders of Vanguard Growth and Income Fund In planning and performing our audit of the financial statements of Vanguard Growth and Income Fund (constituting Vanguard Quantitative Funds, referred to hereafter as the "Fund") as of and for the year ended September 30, 2021, in accordance with the standards of the Public Company Accounting Oversight Board (United States) ("PCAOB"), we considered the Fund's internal control over financial reporting, including controls over safeguarding securities, as a basis for designing our auditing procedures for the purpose of expressing our opinion on the financial statements and to comply with the requirements of Form N- CEN, but not for the purpose of expressing an opinion on the effectiveness of the Fund's internal control over financial reporting. Accordingly, we do not express an opinion on the effectiveness of the Fund's internal control over financial reporting. The management of the Fund is responsible for establishing and maintaining effective internal control over financial reporting. In fulfilling this responsibility, estimates and judgments by management are required to assess the expected benefits and related costs of controls. A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of a company's assets that could have a material effect on the financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. A deficiency in internal control over financial reporting exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent or detect misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company's annual or interim financial statements will not be prevented or detected on a timely basis. Our consideration of the Fund's internal control over financial reporting was for the limited purpose described in the first paragraph and would not necessarily disclose all deficiencies in internal control over financial reporting that might be material weaknesses under standards established by the PCAOB. However, we noted no deficiencies in the Fund's internal control over financial reporting and its operation, including controls over safeguarding securities, that we consider to be a material weakness as defined above as of September 30, 2021. This report is intended solely for the information and use of the Board of Trustees of Vanguard Quantitative Funds and the Securities and Exchange Commission and is not intended to be and should not be used by anyone other than these specified parties. /s/PricewaterhouseCoopers LLP Philadelphia, Pennsylvania November 19, 2021